Egetis Therapeutics

top of page

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.

CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes...

Company News

Sep 16

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.

Follow BiotechTV

Sponsors

Sponsor Spotlight